Verona Pharma plc Pdmr Dealing

 
TIDMVRP 
 
 
   LONDON, March 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that, on March 6, 2019, Dr. David 
Ebsworth, Chairman of the Company, purchased 26,300 ordinary shares of 5 
pence each in the Company (the "Ordinary Shares") at a price of 56.30 
pence per Ordinary Share and a total purchase price of GBP14,806.90 
Following the acquisition, Dr. Ebsworth will have an interest in the 
Company of 217,887 Ordinary Shares, representing 0.21% of the Company's 
issued share capital. 
 
   The notification set out below is provided in accordance with the 
requirements of the EU Market Abuse Regulation. 
 
 
 
 
1   Details of the person discharging managerial responsibilities/person 
     closely associated 
    ---------------------------------------------------------------------- 
a)  Name                                       David Ebsworth 
    -----------------------------------------  --------------------------- 
2   Reason for the notification 
    ---------------------------------------------------------------------- 
a)  Position/status                            Chairman 
    -----------------------------------------  --------------------------- 
b)  Initial notification/Amendment             Initial notification 
    -----------------------------------------  --------------------------- 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    ---------------------------------------------------------------------- 
a)  Name                                       Verona Pharma plc 
    -----------------------------------------  --------------------------- 
b)  LEI                                        213800EVI6O6J3TIAL06 
    -----------------------------------------  --------------------------- 
 
 
 
 
 
 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
    -------------------------------------------------------------------------------------------------------------- 
a)  Description of the financial instrument, type of instrument  Ordinary Shares of 5 pence each 
     Identification code                                          GB00BYW2KH80 
    -----------------------------------------------------------  ------------------------------------------------- 
b)  Nature of the transaction                                    David Ebsworth purchased 26,300 Ordinary Shares 
    -----------------------------------------------------------  ------------------------------------------------- 
 
c)  Price(s) and volume(s)                                           Price(s)                 Volume(s) 
    -----------------------------------------------------------  -----------------  ------------------------------ 
                                                                 56.30 pence per    26,300 Ordinary Shares 
                                                                 Ordinary Share 
    -----------------------------------------------------------  -----------------  ------------------------------ 
d)  Aggregated information                                       N/A 
     - Aggregated volume 
     - Price 
    -----------------------------------------------------------  ------------------------------------------------- 
e)  Date of the transaction                                      6 March 2019 
    -----------------------------------------------------------  ------------------------------------------------- 
f)  Place of the transaction                                     London Stock Exchange, AIM 
    -----------------------------------------------------------  ------------------------------------------------- 
 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer       [e-mail] 
 Victoria Stewart, Director of Communications 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: [phone] 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
 
 
 

(END) Dow Jones Newswires

March 07, 2019 03:14 ET (08:14 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.